VAP expanded cholesterol test can help clinicians identify best treatment
options for patients at risk of heart disease
BIRMINGHAM, Ala., March 7 /PRNewswire/ -- Atherotech, Inc., a cardio-diagnostic company, today announced it will be exhibiting its VAP Cholesterol Test(R) in Booth 21041 at the American College of Cardiology (ACC) 57th Annual Scientific Session Exposition. The annual meeting takes place March 29-April 1, 2008, at the McCormick Place Convention Center in Chicago, Ill.
People with a family history or an existing condition of diabetes, high blood pressure or heart disease -- or who are already taking cholesterol lowering medication -- are candidates for the comprehensive VAP Test. In addition, those who didn't score within the desirable ranges of the standard cholesterol test (i.e. those with Triglycerides > 150, HDL < 40, LDL > 130, Total Cholesterol > 200) should also opt for the more detailed VAP Test.
Atherotech representatives will be available to discuss the VAP expanded cholesterol test in Booth 21041, and blood draws will be provided to qualified attendees. Test results will be returned via mail after the conference.
"The ACC conference presents us with an excellent opportunity to get in front of clinicians and explain how detailed risk profiling is changing the way we evaluate and manage dyslipidemias in at-risk patients," said Atherotech Chief Medical Officer James Ehrlich, M.D. "The highly accurate VAP Test allows the clinician to target high-risk patients for specific therapy that could help prevent millions of future heart attacks and strokes."
The VAP (Vertical Auto Profile) Test is the most accurate and
comprehensive cholesterol test available today, measuring 15 separate
components of blood cholesterol as opposed to three in a standard test. The
comprehensive test can identify more than twice the number of lipid
abnormalities (the #1 risk factor of heart disease) than the standard
|SOURCE Atherotech, Inc.|
Copyright©2008 PR Newswire.
All rights reserved